UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The quest for a shared identity in a composite monarchy Review on Le royaume inachevé des ducs de Bourgogne by Élodie Lecuppre-Desjardin

Bijdragen en mededelingen betreffende de geschiedenis der Nederlanden, 2017-12, Vol.132 (4), p.85-92

Robert Stein

2017

Volltextzugriff (PDF)

1323-P: Frequency of Diabetes Team Contacts in Children and Adolescents Using Insulin Pumps

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

Abstract 3819: INCAGN02385 is an antagonist antibody targeting the co-inhibitory receptor LAG-3 for the treatment of human malignancies

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3819-3819

2018

Volltextzugriff (PDF)

The quest for a shared identity in a composite monarchy: Review on Le royaume inachevé des ducs de Bourgogne by Élodie Lecuppre-Desjardin

Bijdragen en mededelingen betreffende de geschiedenis der Nederlanden, 2017-12, Vol.132 (4)

Robert Stein

2017

Volltextzugriff (PDF)

The quest for a shared identity in a composite monarchy: Review on Le royaume inachevé des ducs de Bourgogne by Élodie Lecuppre-Desjardin

Bijdragen en mededelingen betreffende de geschiedenis der Nederlanden, 2017-12, Vol.132 (4), p.85-92

Robert Stein

2017

Volltextzugriff (PDF)

The quest for a shared identity in a composite monarchy: Review on Le royaume inachevé des ducs de Bourgogne by Élodie Lecuppre-Desjardin

Bijdragen en mededelingen betreffende de geschiedenis der Nederlanden, 2017-12, Vol.132 (4)

Robert Stein

2017

Volltextzugriff (PDF)

The impact of focal therapy tumor boards, including prostate magnetic resonance imaging overreads, in refining the selection candidacy for focal therapy patients: A prospective study

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.324-324

2023

Volltextzugriff (PDF)

Can Financial Engineering Cure Cancer?

The American economic review, 2013-05, Vol.103 (3), p.406-411

2013

Volltextzugriff (PDF)

Abstract 7559: Multi-state gene cluster switches determining the adaptive mitochondrial and metabolic landscape of breast cancer

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.7559-7559

2024

Volltextzugriff (PDF)

Disparity between Ki67 measurements and tumor gene expression tests in patients with hormone-sensitive early breast cancer from the OPTIMA preliminary trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.567-567

2022

Volltextzugriff (PDF)

ON THE FORMATION OF ACTIVE REGIONS

The Astrophysical journal, 2012, Vol.753 (1)

2012

Volltextzugriff (PDF)

Abstract PD1-11: Mature survival update of the double-blind placebo-controlled randomised phase II PAKT trial of first-line capivasertib plus paclitaxel for metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PD1-11-PD1-11

2021

Volltextzugriff (PDF)

Abstract 2390: FcgR co-engagement by anti-TIGIT monoclonal antibodies enhances T cell functionality and antitumor immune responses

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2390-2390

2019

Volltextzugriff (PDF)

Impact of neoadjuvant chemotherapy on pathologic outcomes in patients with upper tract urothelial carcinoma undergoing extirpative surgery

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.457-457

2018

Volltextzugriff (PDF)

AGEN2373 is a conditionally-active agonist antibody targeting the costimulatory receptor CD137 for the treatment of human malignancies

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14005-e14005

2019

Volltextzugriff (PDF)

Outcomes of active surveillance for African-American men with prostate cancer: Results of a matched analysis

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.89-89

2019

Volltextzugriff (PDF)

Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.OT3-17-01-OT3-17-01

2020

Volltextzugriff (PDF)

Abstract 2721: Selective FcγR engagement by CTLA-4 antibodies results in increased functional activity

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.2721-2721

2018

Volltextzugriff (PDF)

Abstract 3825: INCAGN02390, a novel antagonist antibody that targets the co-inhibitory receptor TIM-3

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3825-3825

2018

Volltextzugriff (PDF)

Fictional Plots and Historical Explanation: A Response to David Leeson's "Cutting Through History"

Left history, 2004-12, Vol.10 (1), p.47

Stein, Robert M.

2004

Volltextzugriff (PDF)

Phase 1 open-label, multiple ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3075-3075

2017

Volltextzugriff (PDF)

Neoantigen Synthetic Peptide Vaccine for Multiple Myeloma Elicits T Cell Immunity in a Pre-Clinical Model

Blood, 2017-12, Vol.130, p.1868-1868

2017

Volltextzugriff (PDF)

Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3075-3075

2018

Volltextzugriff (PDF)

A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer patients (IRIS) – Trial Results

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.549-549

2016

Volltextzugriff (PDF)

Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3086-3086

2018

Volltextzugriff (PDF)

1 – 25 von 462

Suche als RSS-Feed

Aktive Filter

SpracheFranzösisch

ThemaScience & Technology

KollektionEZB Electronic Journals Library

KollektionNUS Single-Journal Subscriptions

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(366)
Mit Volltextzugriff
(423)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Aba Journal
(80)
Journal Of Clinical Oncology
(65)
Blood
(62)
Cancer Research
(48)
The American Historical Review
(15)
Science
(14)
Biology Of Blood And Marrow Transplantation
(10)
Journal Of Animal Science
(10)
The New England Journal Of Medicine
(9)
Pediatrics
(8)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The quest for a shared identity in a composite monarchy Review on Le royaume inachevé des ducs de Bourgogne by Élodie Lecuppre-Desjardin

1323-P: Frequency of Diabetes Team Contacts in Children and Adolescents Using Insulin Pumps

Abstract 3819: INCAGN02385 is an antagonist antibody targeting the co-inhibitory receptor LAG-3 for the treatment of human malignancies

The quest for a shared identity in a composite monarchy: Review on Le royaume inachevé des ducs de Bourgogne by Élodie Lecuppre-Desjardin

The quest for a shared identity in a composite monarchy: Review on Le royaume inachevé des ducs de Bourgogne by Élodie Lecuppre-Desjardin

The quest for a shared identity in a composite monarchy: Review on Le royaume inachevé des ducs de Bourgogne by Élodie Lecuppre-Desjardin

The impact of focal therapy tumor boards, including prostate magnetic resonance imaging overreads, in refining the selection candidacy for focal therapy patients: A prospective study

Can Financial Engineering Cure Cancer?

Abstract 7559: Multi-state gene cluster switches determining the adaptive mitochondrial and metabolic landscape of breast cancer

Disparity between Ki67 measurements and tumor gene expression tests in patients with hormone-sensitive early breast cancer from the OPTIMA preliminary trial

ON THE FORMATION OF ACTIVE REGIONS

Abstract PD1-11: Mature survival update of the double-blind placebo-controlled randomised phase II PAKT trial of first-line capivasertib plus paclitaxel for metastatic triple-negative breast cancer

Abstract 2390: FcgR co-engagement by anti-TIGIT monoclonal antibodies enhances T cell functionality and antitumor immune responses

Impact of neoadjuvant chemotherapy on pathologic outcomes in patients with upper tract urothelial carcinoma undergoing extirpative surgery

AGEN2373 is a conditionally-active agonist antibody targeting the costimulatory receptor CD137 for the treatment of human malignancies

Outcomes of active surveillance for African-American men with prostate cancer: Results of a matched analysis

Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer

Abstract 2721: Selective FcγR engagement by CTLA-4 antibodies results in increased functional activity

Abstract 3825: INCAGN02390, a novel antagonist antibody that targets the co-inhibitory receptor TIM-3

Fictional Plots and Historical Explanation: A Response to David Leeson's "Cutting Through History"

Phase 1 open-label, multiple ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies

Neoantigen Synthetic Peptide Vaccine for Multiple Myeloma Elicits T Cell Immunity in a Pre-Clinical Model

Phase I open-label, ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies: Dose selection for combination with PD-1 blockade

A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer patients (IRIS) – Trial Results

Phase 1/2 open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation

Aktive Filter

Suchergebnisse filtern